Panafcortelone 1mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

panafcortelone 1mg tablet bottle

aspen pharmacare australia pty ltd - prednisolone, quantity: 1 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; magnesium stearate; crospovidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder

PANAFCORT prednisone 25 mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

panafcort prednisone 25 mg tablet bottle

aspen pharmacare australia pty ltd - prednisone, quantity: 25 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; crospovidone; lactose monohydrate; magnesium stearate; macrogol 6000 - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder

DEXMETHSONE dexamethasone 0.5mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

dexmethsone dexamethasone 0.5mg tablet bottle

aspen pharmacare australia pty ltd - dexamethasone, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; magnesium stearate; wheat starch - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; andrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephroticsyndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder.

DEXMETHSONE dexamethasone 4mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

dexmethsone dexamethasone 4mg tablet bottle

aspen pharmacare australia pty ltd - dexamethasone, quantity: 4 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; magnesium stearate; lactose monohydrate - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; andrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephroticsyndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder.

Ovestin 1mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ovestin 1mg tablet blister pack

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg - tablet, uncoated - excipient ingredients: amylopectin; potato starch; lactose monohydrate; magnesium stearate - short-term treatment of menopausal syndrome. review the need for continuation of treatment after 6 months treatment, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, refer to clinical trials and precautions). ovestin tablets should only be continued for as long as the benefit outweighs the risks.

SEVIKAR HCT 40/5/25 olmesartan medoxomil 40 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 25 mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sevikar hct 40/5/25 olmesartan medoxomil 40 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 25 mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg) - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

SEVIKAR HCT 40/5/12.5 olmesartan medoxomil 40 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 12.5 mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sevikar hct 40/5/12.5 olmesartan medoxomil 40 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 12.5 mg tablet blister pack

organon pharma pty ltd - amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg); olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

SEVIKAR HCT 40/10/12.5 olmesartan medoxomil 40 mg amlodipine (as besilate) 10 mg and hydrochlorothiazide 12.5mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sevikar hct 40/10/12.5 olmesartan medoxomil 40 mg amlodipine (as besilate) 10 mg and hydrochlorothiazide 12.5mg tablet blister pack

organon pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty mg); olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

SEVIKAR HCT 40/10/25 olmesartan medoxomil 40 mg amlodipine (as besilate) 10 mg and hydrochlorothiazide 25 mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sevikar hct 40/10/25 olmesartan medoxomil 40 mg amlodipine (as besilate) 10 mg and hydrochlorothiazide 25 mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg/mg (equivalent: amlodipine, qty mg); hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

SEVIKAR HCT 20/5/12.5 olmesartan medoxomil 20 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 12.5mg tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sevikar hct 20/5/12.5 olmesartan medoxomil 20 mg amlodipine (as besilate) 5 mg and hydrochlorothiazide 12.5mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg); hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy